comparemela.com

Latest Breaking News On - Julio gay ger - Page 1 : comparemela.com

Undeniable benefits of high-level opening-up

Recent COVID-19 cases on the Chinese mainland are distinct in terms of their impact on business sentiment. Unlike the outbreak in March, this time, people don't seem worried too much about the possible impact of COVID-19 on exports and economic prospects.

Innovent and Lilly Jointly Announce the Approval of TYVYT® (sintilimab injection) by China NMPA in Combination with Chemotherapy as First-line Treatment of Advanced or Metastatic Gastric or Gastro

Innovent and Lilly Jointly Announce the Approval of TYVYT (sintilimab injection) by China NMPA in Combination with Chemotherapy as First-Line Treatment for Esophageal Squamous Cell Carcinoma

SAN FRANCISCO, INDIANAPOLIS and SUZHOU, China, June 21, 2022 /PRNewswire/ Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, autoimmune, metabolic, ophthalmology and other major diseases, and Eli Lilly and Company ("Lilly", NYSE: LLY) today announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has approved the supplemental New Drug Application (sNDA) for TYVYT (sintilimab injection) in combination with cisplatin plus paclitaxel or cisplatin plus 5-fluorouracil chemotherapy for the first-line treatment of unresectable, locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC). This is the fifth NMPA-approved indication of TYVYT. In China, TYVYT was approved for: the treatment of relapsed or refractory classical Hodgkin's lymphoma in Dece

Innovent and Lilly Jointly Announce the Approval of TYVYT® (sintilimab injection) by China NMPA in Combination with Chemotherapy as First-Line Treatment for Esophageal Squamous Cell Carcinoma

Global pharma giants step up alliances in Chinese market

Global pharma giants step up alliances in Chinese market By ZHOU WENTING in Shanghai | China Daily | Updated: 2021-04-08 09:46 Share CLOSE United States-based pharmaceutical company Eli Lilly s booth at the third China International Import Expo in Shanghai last year. [Photo/Xinhua] Multinationals accelerating cooperation for enhanced growth, breakthroughs Research and development collaborations between multinational pharmaceutical companies and innovative local Chinese biotech enterprises have begun to bear fruit as some have already jointly developed products in the country that have benefited patients overseas. Today s China, the world s second-largest economy and medical consumption market, is not merely a sales opportunity for multinational pharmaceutical giants but also a major platform for medical research and development, said industry insiders.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.